GlassScriptPhysician profile
Salah Al-Abbadi
NPI 1649452301
$1,844.32
in general payments reported to CMS, 2019-2025
22 companies · $236 in 2025
The $236 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $399 · 2021: $454 · 2022: $52.03 · 2023: $109 · 2024: $260 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $560 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $559.57 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $399.19 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $299.71 | 2020-2024 | Breztri |
| Lilly USA, LLC | $203.47 | 2021-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $196.43 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $193.77 | 2021-2024 | Rexulti, Abilify Maintena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.77 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $59.91 | 2019-2020 | |
| Allergan, INC. | $59.05 | 2019-2020 | |
| Axsome Therapeutics, INC. | $40.40 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $35.50 | 2024 | Ingrezza |
| Adlon Therapeutics L.P. | $30.44 | 2020-2021 | |
| Alkermes, INC. | $25.29 | 2023 | Lybalvi |
| Beckman Coulter, INC. | $24.20 | 2024 | Unicel Dxi Access |
| Novartis Pharmaceuticals Corporation | $20.85 | 2023 | |
| Sanofi-Aventis U.S. LLC | $18.97 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $17.32 | 2021 | |
| Avanir Pharmaceuticals, INC. | $15.91 | 2022 | |
| Merck Sharp & Dohme LLC | $14.62 | 2019 | |
| Hikma Pharmaceuticals USA | $14.44 | 2021 | |
| Eyevance Pharmaceuticals LLC | $14.44 | 2021 | |
| Amgen INC. | $13.96 | 2023 | Prolia, Evenity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.68 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salah Al-Abbadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.